Skip to content

Testosterone Topical

    DEA Class; Rx

    Common Brand Names; Androderm, AndroGel, Testim, Axiron, Fortesta, Vogelxo

    • Androgens

    Primary androgen in humans synthesized by testes, ovaries, and adrenal cortex; available in a variety of dosage forms
    Primarily used in males with primary hypogonadism or with hypogonadism due to medical conditions; may be used for a limited duration for constitutional delay of puberty; used off-label in men with sexual dysfunction due to low testosterone associated with aging
    Not recommended for low testosterone status alone due to aging due to potential risk for cardiovascular events and stroke

    Primary hypogonadism (congenital or acquired): Testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter Syndrome, chemotherapy, or toxic damage from alcohol or heavy metals; these men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above normal range

    Hypogonadotropic hypogonadism (congenital or acquired): Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation; these men have low testosterone serum concentrations but have gonadotropins in the normal or low range

    Males with breast or prostate cancer

    Hypersensitivity

    Breast feeding women

    Pregnancy

    • Pruritus at application site (37%)
    • Skin reactions at application site (16.1%)
    • Blisters under skin (12%)
    • Erythema at application site (7%)
    • Vesicles at application site (6%)
    • Allergic contact dermatitis (4%)
    • Burning at application site (3%)
    • Induration at application site (3%)
    • Abnormal dreams
    • Acne
    • Anaphylaxis
    • Bladder irritability
    • Breast soreness
    • Cholestatic jaundice
    • Deep vein thrombosis
    • Dry skin
    • Fatigue
    • Gynecomastia
    • Headache
    • Insomnia
    • Menstrual irregularities
    • Priapism
    • Suppression of factors II, V, VII
    • Virilization

    Use with caution in patients with chronic lung disease, obesity, advanced age, or preexisting cardiac, renal, or hepatic disease

    Employ caution with prolonged use of high doses, which may be associated with hepatic effects

    May increase risk of prostate cancer

    Risk of gynecomastia when used for male hypogonadism

    May change serum lipid profile; use with caution in patients who have history of mycoardial infarction (MI) or coronary artery disease (CAD)

    Large doses may suppress spermatogenesis

    May increase hematocrit, which requires dose adjustment or discontinuation; monitor serum testosterone, prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit and hemoglobin periodically

    May cause hypercalcemia in patients with prolonged immolibization or cancer

    Anabolic activity of androgens may enhance hypoglycemia

    Children: Risks of inappropriate genital enlargement, premature pubic hair, advanced bone age, increased libido, and aggressive behavior

    Fortesta: Exogenous administration of androgens may lead to azoospermia; sleep apnea may occur in those with risk factors; preparation is flammable until dry

    Discontinue if urethral obstruction develops in patients with benign prostatic hyperplasia (BPH); monitor patients with BPH for worsening of signs and symptoms of BPH

    Edema with or without congestive heart failure, may be a complication in patients with pre-existing cardiac, renal, or hepatic disease; use with caution

    May worsen sleep apnea in some male patients

    Evaluate patients for cardiovascular risk factors prior to initiating therapy and monitor closely during therapy

    Use caution in patients with diseases that may be exacerbated by fluid retention, including cardiac, hepatic, or renal dysfunction; not recommended for men with poorly controlled heart failure

    Monitor women for virilization when treating for metastatic breast cancer

    Geriatric patients may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and increase in transaminase levels

    Increased hematocrit (polycythemia), reflective of increased red blood cell mass, may require discontinuation; increases risk for thromboemolism

    Venous thromboembolism, including DVT and PE reported in patients using testosterone products; these observations have included patients with and without polycythemia; evaluate signs or symptoms consistent with DVT or PE; if venous thromboembolic event suspected, discontinue treatment with testosterone and initiate appropriate workup and management

    Contraindicated in pregnant women; drug is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action; exposure of female fetus to androgens may result in varying degrees of virilization

    Drug is not indicated for use in women

    Adults

    Dependent on indication for therapy, as well as route of administration and specific product chosen for use.

    Geriatric

    Dependent on indication for therapy, as well as route of administration and specific product chosen for use.

    Adolescents

    Dependent on indication for therapy, as well as route of administration and specific product chosen for use.

    Children

    Dependent on indication for therapy, as well as route of administration and specific product chosen for use.

    Infants

    Safety and efficacy have not been established.

    Testosterone Topical

    patch, transdermal: Schedule III

    • 2mg/24hr
    • 4mg/24hr

    gel, transdermal: Schedule III

    • 1% (12.5mg/actuation) (Androgel)
    • 1.62% (20.25mg/actuation) (Androgel)
    • 10mg/actuation (1 pump actuation dispenses 0.5 g of gel) (Fortesta)
    • 12.5mg/actuation (Vogelxo)
    • 20.25mg/1.25g
    • 25mg/2.5g
    • 40.5mg/2.5g
    • 50mg/5g (Testim)
    • 50mg/unit dose pack (Vogelxo)

    ointment, topical: Schedule III

    • 2%

    solution, topical: Schedule III

    • 30mg/actuation (90mL) (Axiron)

    cream, transdermal: Schedule III

    • 2%